Meet the Team


Biomedical and Matrix Diagnostics Biosystems, and he advises several startups including
Shasqi, Valitor, Modern Meadow, and others. He is a 2018 Fellow of the AAAS, a 2013
Fellow of the National Academy of Inventors, recipient of the 2006 Utah Governor’s
Medal for Science and Technology, the 2008 Volwiler Research Award of the AACP, the
2010 University of Utah Distinguished Scholarly and Creative Research Award, and the
2014 U of Utah Distinguished Innovation and Impact Award. During his 42 years as a
faculty member, he has over 665 publications (H-index 94) and over 48 issued patents
and has trained over 125 postgraduate scientists. He is a pilot for Angel Flight West and a
passionate advocate for chamber music. Glenn completed his postdoctoral training at Cornell University, and holds a PhD from Stanford University and a B.S. from California Institute of Technology, all in chemistry.


Bill has led numerous successful medical device projects at AorTech and Closure Medical, directed large R&D programs and teams at Ethicon and Allergan, and founded both an additive manufacturing medical technology firm and a medical product consulting firm.
Most recently, he has been leading the R&D team at Focal Medical in developing a novel drug delivery platform. This platform is now IND-cleared for a Phase 1b clinical trial for pancreatic cancer, with additional applications in oral cancer and drug-resistant skin melanoma.
Bill’s technical specialties include bioadhesives and sealants, the use of additive manufacturing in the design and development of medical devices, soft tissue repair and reconstruction technologies, and combination products for drug delivery. He has a significant track record of successful US and international regulatory submissions (Class II and III).
In addition to his role at Maana Discoveries, Bill advises several startups, including Rilento Pharma and Additive Medical. He also served as a team leader for NIH's RADx program, working to fast-track diagnostics technologies through regulatory clearance to commercialization during the COVID-19 pandemic. More recently, he is serving as a mentor in the NIH Blueprint MedTech program for developing commercial-ready neurotechnology devices, as well as the NIH Rock Mountain Reach hub.
Bill holds a PhD and a BSc from the University of Akron, both in chemistry.
